Scotsman: Bad Day: Pfizer Investors

ITS shares fell 12 per cent in New York after the world’s biggest drugmaker surprised the market by abandoning the development of its leading experimental cholesterol treatment, torcetrapib.

Read the full article at

Leave a Comment

Your email address will not be published. Required fields are marked *